A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia
Status:
Completed
Trial end date:
2014-01-16
Target enrollment:
Participant gender:
Summary
This research is being done because SB939 has been shown to shrink tumours in animals and in
some people and seems promising, but we are not sure if it can offer better results than
standard treatment.